antibody drawn as a superhero fighting tumour drawn as a supervillain

Improving anticancer activity of antibody–drug conjugates

Learn more about this and other topics in our March issue

  • Kyoji Tsuchikama
  • Yasuaki Anami
  • Chisato M. Yamazaki
Review Article

Announcements

  • charts overlaid with maps

    In this Collection, you can find the latest articles published in Nature Reviews Clinical Oncology that discuss trends in cancer incidence and mortality.

  • viral particles floating

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic.

  • four diverse women together

    This regularly updated collection of articles published in the Nature Reviews journals provides in-depth discussions of recent research and medical advances in fields covering women’s health in the broadest sense. These health conditions can affect cisgender, transgender, intersex and/or non-binary people with female-specific organs and hormonal cycles.

  • electronic microscope image of cancer cells and T cells together

    Join Nature Reviews Immunology, Nature Immunology, Nature Medicine and Nature Cancer in a Nature Conference co-organised with the Dana Farber Cancer Institute on June 10-12 in Boston. Submit your abstract by April 12, 2024.

Advertisement

    • Copper is an essential trace element with inherent redox properties and fundamental roles in a diverse range of biological processes; therefore, maintaining copper homeostasis is crucial. In this Review, the authors discuss new insights into the mechanisms by which disrupted copper homeostasis contributes to tumour initiation and development, including the recently defined concepts of cuproplasia (copper-dependent cell growth and proliferation) and cuproptosis (a mitochondrial pathway of cell death triggered by excessive copper exposure). They also discuss potential strategies to exploit cuproplasia and cuproptosis for the treatment of cancer.

      • Daolin Tang
      • Guido Kroemer
      • Rui Kang
      Review Article
    • The benefits and potential harms of mammography-based screening for breast cancer are often a matter of debate. Here, I discuss the promises and limitations of a recent study that tested an artificial intelligence-based tool for the detection of breast cancer in digital mammograms in a large, prospective screening setting.

      • Despina Kontos
      News & Views
    • FGFR inhibitors are now approved for use in patients with advanced-stage urothelial carcinoma, cholangiocarcinoma and myeloid or lymphoid neoplasms that harbour certain FGFR alterations. Nonetheless, challenges such as tolerability and acquired resistance limit the clinical potential of these agents. In this Review, the authors summarize the available clinical data on FGFR inhibitors, describe promising novel agents and highlight future research directions that might optimize the efficacy of FGFR-targeted therapies.

      • Masuko Katoh
      • Yohann Loriot
      • Masaru Katoh
      Review Article
    • Patients with early stage hepatocellular carcinoma typically undergo resection, liver transplantation or local ablation; however, 30–50% will have disease recurrence at 3 years. The authors of this Review describe the tumour immune microenvironment and mechanism of action of immunotherapies, and discuss the available evidence from phase II/III trials of neoadjuvant and adjuvant treatment approaches in this setting.

      • Josep M. Llovet
      • Roser Pinyol
      • Richard S. Finn
      Review Article
    • Increasing evidence indicates that signalling networks activated downstream of oncogenic alterations contribute fundamentally to cancer immune evasion, including by promoting the accumulation of regulatory T (Treg) cells and other immunosuppressive cells in the tumour microenvironment (TME). Herein, the authors discuss the mechanisms via which cancers engage Treg cells to evade antitumour immunity, as well as the characteristics of Treg cells in the TME and their roles in resistance to immune-checkpoint inhibitors. Considering these aspects, they propose the concept of ‘immuno-genomic cancer evolution’ for tumorigenesis and the related paradigm of ‘immuno-genomic precision medicine’, postulating that the specific characteristics of cancer, especially genetic profiles that correlate with particular immunosuppressive networks in the TME, are likely to inform individualized strategies for combining molecularly targeted agents with immunotherapies.

      • Shogo Kumagai
      • Kota Itahashi
      • Hiroyoshi Nishikawa
      Review Article

Nature Careers

Science jobs

Advertisement